Oral Iron for Iron-Deficiency Anemia in Menstruating Adolescent Girls: What Works, Which Products Have Been Studied, Safety, Tolerability, and Cost-Effectiveness
Updated: Sep 24
Abstract
Iron deficiency and iron-deficiency anemia (IDA) are common during adolescence, particularly after menarche. Menstrual blood loss, rapid growth, insufficient dietary iron, restrictive eating patterns, athletic participation, and heavy menstrual bleeding can contribute to depletion of iron stores. The clinical question is not simply whether iron supplementation works, but which formulation provides the best combination of hemoglobin response, restoration of ferritin, tolerability, adherence, safety, and cost.
Recent pediatric guidance continues to support oral iron as first-line therapy for most uncomplicated cases. Ferrous salts, particularly ferrous sulfate, remain the most extensively studied and generally least expensive treatments. Newer preparations—including ferric maltol, iron polymaltose, iron bisglycinate, liposomal iron, and sucrosomial iron—may offer advantages in taste or gastrointestinal tolerability, but evidence that they consistently outperform inexpensive ferrous sulfate in menstruating adolescent girls is limited. The newest pediatric randomized evidence shows that ferric maltol and ferrous sulfate both improve hemoglobin, while newer liposomal formulations also appear effective; however, the studies are substantially smaller and less specific to post-menarche girls than the evidence base supporting conventional oral iron.
The practical conclusion is that ferrous sulfate remains the reference first-line treatment when tolerated and taken consistently. More expensive formulations are reasonable alternatives when gastrointestinal intolerance, taste, adherence, malabsorption, or treatment failure interferes with successful therapy, but their higher price should not automatically be interpreted as greater efficacy.
1. Why Menstruating Adolescent Girls Are a Distinct High-Risk Group
Iron requirements increase during adolescence because of rapid growth and expansion of blood volume. After menarche, menstrual blood loss adds another continuing source of iron loss. Adolescents with heavy menstrual bleeding, restrictive eating patterns, vegetarian or vegan diets, intensive athletic activity, inflammatory disease, or eating disorders may be at particularly high risk. A 2024 review specifically addressing adolescents emphasizes excessive menstrual loss as an important cause and recommends treatment of confirmed deficiency until iron stores—not only hemoglobin—have recovered.
Recent American Academy of Pediatrics guidance recommends particular attention to menstruating adolescents. The 2026 clinical report considers serum ferritin ≤30 ng/mL consistent with iron deficiency in adolescents and menstruating individuals, while noting that ferritin interpretation must take inflammation into account.
This distinction matters because a girl can have depleted iron stores before hemoglobin becomes frankly abnormal. Conversely, low hemoglobin should not automatically be attributed to iron deficiency without considering other causes.
Heavy menstrual bleeding deserves particular attention. ACOG recommends assessing adolescents with heavy menstrual bleeding for anemia, including serum ferritin, while also considering endocrine abnormalities and bleeding disorders.
2. Does Oral Iron Actually Correct Low Hemoglobin and Low Ferritin?
Yes. The evidence that oral iron corrects iron deficiency and IDA is strong.
A recent 2025 systematic review of pediatric IDA interventions included patients up to 18 years of age. Both oral and intravenous iron increased hemoglobin substantially. The pooled hemoglobin increase with oral therapy was approximately 22.08 g/L, or 2.21 g/dL, although the included studies were heterogeneous.
For adolescent girls specifically, contemporary school-based studies also demonstrate benefit. In a 2021 cluster-randomized trial involving adolescent girls aged 12–19 years with mild-to-moderate anemia, 90 days of supervised iron-folic acid supplementation increased hemoglobin by approximately 1.3–1.6 g/dL and substantially improved ferritin status. Adding 1,000 μg of vitamin B12 did not provide an additional hemoglobin advantage over iron-folic acid alone.
A 2024 systematic review and meta-analysis that searched MEDLINE, Scopus, Web of Science, Cochrane Library, and Google Scholar found that weekly iron-folic acid supplementation increased ferritin in adolescent girls and reduced anemia risk by approximately 20% across children and adolescents in the included studies.
These data establish an important distinction: iron replacement works when iron deficiency is actually present. Additional vitamins do not necessarily improve the hematologic response unless those nutrients are also deficient.
3. Which Iron Form Works Best?
Ferrous sulfate: still the benchmark
Ferrous sulfate has several advantages that newer products have not displaced: a large evidence base, predictable elemental-iron content, worldwide availability, and low cost.
The American Gastroenterological Association's 2024 clinical update concluded that no oral iron formulation has demonstrated a general clinical advantage sufficient to displace ferrous sulfate and specifically favored ferrous sulfate because it is the least expensive. The AAP's 2026 pediatric guidance similarly describes ferrous sulfate as the least costly, most widely available, and most extensively studied oral iron preparation.
A 2021 systematic review and meta-analysis comparing iron polymaltose with other oral iron treatments in children found ferrous sulfate superior to iron polymaltose for both hemoglobin and ferritin restoration. Hemoglobin favored ferrous sulfate by approximately 0.81 g/dL and ferritin by approximately 21 μg/L. Importantly, gastrointestinal adverse effects were not significantly different between the two treatments.
That finding weakens a common marketing assumption that a more expensive ferric complex necessarily provides equal hematologic efficacy with substantially fewer adverse effects.
4. Daily Versus Alternate-Day Iron
Traditional treatment often involved iron several times per day. Contemporary evidence increasingly questions that approach because oral iron temporarily increases hepcidin, which can reduce absorption of subsequent doses.
The 2024 adolescent review recommends oral iron no more than once daily, ideally in the morning.
Recent pediatric evidence is also moving toward simplified dosing. A 2025 randomized pediatric trial found alternate-day oral iron associated with improved hemoglobin, lower hepcidin, and fewer gastrointestinal adverse effects compared with twice-daily therapy, although the participants were younger than the population of interest here.
A 2026 pediatric cohort found daily and alternate-day ferrous sulfate broadly comparable after three months, although daily treatment produced a somewhat faster initial response.
A 2025 meta-analysis concluded that daily and alternate-day administration appear similarly effective overall, with possible tolerability advantages for alternate-day dosing, but rated much of the evidence as low or very-low certainty.
Therefore, alternate-day treatment is a reasonable adherence/tolerability strategy, not yet proof that every adolescent should receive iron every other day.
5. Commercial Products Actually Used in Research
A major limitation of the literature is that many trials state only “ferrous sulfate,” “iron-folic acid,” or another chemical formulation without identifying the commercial manufacturer. The following products can be linked to an actual research preparation with reasonable confidence.
Research product | Formulation / company reported in research | Population | Main finding | Relevance to menstruating girls |
Ferrous sulfate / generic IFA | Brand frequently not reported in contemporary public-health trials | Adolescent girls 12–19 | Hb ↑ ~1.3–1.6 g/dL after 90 days; ferritin improved | Direct evidence |
ACCRUFeR® / ferric maltol | Pediatric trial sponsored by Shield Therapeutics; ACCRUFeR is the U.S. branded ferric-maltol product | Ages 2–17; median 14; 73.8% female | Ferric maltol and ferrous sulfate both increased Hb; ferric maltol better taste/tolerability ratings, while ferritin rose more with ferrous sulfate | Very relevant recent adolescent evidence, although not exclusively menstruating girls |
Maltofer® | Iron(III)-hydroxide polymaltose; Vifor (International) Inc., Switzerland, as reported in the study | Adolescents, both sexes | 100 mg elemental iron 6 d/week for 8 months corrected ID/IDA and improved stores; no adverse effects reported | Direct adolescent evidence, but old (2008) and not female-only |
Feosol® | Ferrous sulfate; SmithKline Beecham, as reported at time of study | Iron-deficient, nonanemic adolescent girls | Ferritin improved and cognitive outcomes were investigated | Female-specific but very old evidence; dose was much higher than current commonly favored regimens |
FORTIFERRUM / SunActive iron | Liposomal SunActive; A.E.I. 24, Spain, as reported in trial | Children 2–12 | Better Hb/iron indices and adherence than comparator after treatment | Promising, but indirect for post-menarche adolescents |
HYDROFERRIN | Iron polymaltose complex; Borg Pharmaceutical Industries, Egypt | Children 2–12 | Effective, but inferior to FORTIFERRUM in that trial | Indirect evidence |
Ferrochel® | Ferrous bisglycinate chelate; Albion Laboratories Inc. | Children 1–13 | Improved Hb; ferritin response favored bisglycinate over polymaltose in small trial | Limited and indirect; older study |
Noripurum® | Polymaltose iron; Takeda Pharma Ltda., as reported in trial | Children 1–13 | Hb improved; ferritin response less impressive than bisglycinate | Limited and indirect |
Important interpretation of brand evidence
The existence of a study involving a named product does not prove that the commercial brand is superior to generic iron.
This is especially important for products such as Maltofer, Ferrochel, ferric maltol, liposomal iron, and sucrosomial iron. Many studies are small, include broader pediatric or adult populations, or have industry involvement.
For example, the 2008 Maltofer adolescent study included an author employed by Vifor. That does not invalidate the findings, but it should be disclosed when interpreting the evidence.
Similarly, the recent pediatric ferric-maltol trial was sponsored by Shield Therapeutics.
6. Ferric Maltol: One of the Most Interesting New Adolescent Options
Ferric maltol deserves particular attention because new evidence directly includes adolescents.
A 2026 phase 3 multicenter trial included 61 children and adolescents aged 2–17 years, with a median age of 14; 45 participants were female. Both ferric maltol and ferrous sulfate improved hemoglobin over 12 weeks.
The descriptive Hb increases were approximately:
Ferric maltol: +1.25 g/dL
Ferrous sulfate: +1.15 g/dL
Adverse events occurred in approximately 29% and 30%, respectively, but treatment-related adverse reactions were more frequently attributed to ferrous sulfate. Ferric maltol also received better taste and smell ratings. Interestingly, ferritin increased more with ferrous sulfate, which is relevant because correction of iron stores is an important treatment objective.
The FDA's current labeling reports a pediatric subgroup of 24 patients aged 10–17 treated with ACCRUFeR, including 20 females. Mean hemoglobin increased approximately 1.10 g/dL at 12 weeks, and mean ferritin increased from 11.4 to 20 μg/L.
This makes ferric maltol an evidence-supported option, particularly when conventional iron is poorly tolerated. It does not, however, demonstrate superior hematologic efficacy or better cost-effectiveness than inexpensive ferrous sulfate.
7. Iron Polymaltose: Effective, But Probably Not the Most Efficient First Choice
Iron polymaltose clearly can treat iron deficiency. The older Maltofer adolescent study demonstrated improvements in anemia and iron stores.
However, when broader randomized pediatric evidence is pooled, ferrous sulfate performs better.
The 2021 systematic review found that iron polymaltose produced a smaller improvement in Hb and ferritin than ferrous sulfate, without a convincing reduction in adverse effects.
Therefore:
Polymaltose works.
But current evidence does not establish it as more effective or more cost-effective than ferrous sulfate.
It remains a reasonable alternative when taste or individual tolerability favors it.
8. Iron Bisglycinate
Ferrous bisglycinate is commonly marketed as a gentler, better-absorbed form of iron.
There is biological plausibility and some clinical evidence supporting it, but direct evidence in menstruating adolescent girls with established IDA remains sparse.
An older randomized pediatric study used Ferrochel®, Albion Laboratories, versus Noripurum®, Takeda, at equivalent elemental-iron doses. Both improved hemoglobin, but only the bisglycinate group produced a statistically significant ferritin increase in that small trial.
A 2026 systematic review in active females also identified Ferrochel as a studied ferrous-bisglycinate preparation, although much of that literature concerns iron deficiency without frank anemia and athletic populations rather than adolescent IDA.
The evidence is therefore promising but insufficient to claim that iron bisglycinate should replace ferrous sulfate as first-line therapy for anemic adolescent girls.
9. Liposomal and Sucrosomial Iron
These technologies attempt to improve absorption and gastrointestinal tolerance by encapsulating iron.
A 2025 randomized pediatric trial compared FORTIFERRUM, containing liposomal SunActive iron manufactured by A.E.I. 24 in Spain, with HYDROFERRIN iron polymaltose from Borg Pharmaceutical Industries in Egypt.
The SunActive group showed higher hemoglobin, ferritin, serum iron, and transferrin saturation and had less treatment refusal.
A 2026 meta-analysis of four pediatric RCTs involving 454 children found that liposomal iron was generally noninferior to conventional iron for hematologic outcomes and was associated with fewer adverse events and less constipation; a greater Hb increase appeared at six months, but heterogeneity was substantial.
That is encouraging, but most of these participants were not post-menarche adolescent girls.
Sucrosomial iron also has favorable tolerability data, but much of the evidence comes from adult populations and some reviews have industry connections. The 2023 review includes authors employed by Alesco and Pharmanutra, companies involved in sucrosomial-iron technology.
Consequently, I would characterize liposomal/sucrosomial iron as:
Promising alternatives for intolerance or adherence problems—not proven superior first-line therapy for menstruating adolescent girls.
10. What Does Not Appear to Add Much Benefit?
Several conclusions are reasonably clear.
Adding vitamin B12 to iron-folic acid does not improve hemoglobin when the additional B12 is not needed. In the adolescent-girl RCT discussed above, both groups improved, but adding 1,000 μg cyanocobalamin provided no additional Hb advantage.
Similarly, folic acid does not substitute for iron when depleted iron stores are the cause of anemia. Older adolescent studies found ferritin declining when folic acid was given without iron in girls with low iron status.
Premium formulations also should not be assumed to work better simply because they are labeled “gentle,” “chelated,” “liposomal,” or “advanced absorption.”
The evidence supports paying for them primarily when they solve an actual clinical problem—such as intolerance, refusal, adherence failure, or poor response—not merely because they are newer.
Finally, ordinary low-dose multivitamins and many iron gummies are not equivalent to therapeutic iron replacement. Their elemental iron content may be inadequate for treating established IDA.
11. Safety
For most adolescents, oral iron is safe when appropriately prescribed. Common adverse effects are nausea, abdominal discomfort, constipation, diarrhea, metallic taste, and dark stools. Liquid formulations may temporarily stain teeth.
Ferrous sulfate's main clinical weakness is gastrointestinal tolerability rather than lack of efficacy.
More frequent dosing can increase side effects, which is one reason once-daily or alternate-day regimens are receiving increasing attention.
Iron also deserves a particularly strong child-safety warning: accidental ingestion of large amounts can cause severe and potentially fatal iron poisoning. Products should therefore be stored securely away from younger children.
Iron supplementation also should not become a substitute for identifying the source of blood loss.
In a menstruating adolescent with substantial iron deficiency, clinicians should specifically ask about duration of menstruation, number of pads/tampons used, flooding or leakage, large clots, bleeding through clothes or bedding, prolonged bleeding, easy bruising, epistaxis, family bleeding history, dietary restriction, and gastrointestinal symptoms. ACOG specifically recommends consideration of bleeding disorders in adolescents presenting with heavy menstrual bleeding.
12. Cost-Effectiveness
This is where conventional ferrous sulfate remains difficult to beat.
The 2024 AGA guidance explicitly favors ferrous sulfate because no formulation has demonstrated a sufficiently consistent efficacy advantage and ferrous sulfate is the least expensive.
The 2026 AAP report reaches a similar practical conclusion: ferrous sulfate is inexpensive, widely available, and well studied, while some alternative complexes can be considerably more costly.
Newer formulations can nevertheless become economically reasonable when intolerance causes treatment failure. A supplement that costs three times more but is actually taken may be more useful than inexpensive tablets left in the bottle.
However, there is currently little high-quality cost-effectiveness research specifically comparing ferrous sulfate, ferric maltol, bisglycinate, liposomal iron, and polymaltose in menstruating adolescent girls.
Adult cost-minimization analyses exist for sucrosomial iron, including comparisons with intravenous therapy, but those findings cannot legitimately be transferred directly to otherwise healthy adolescent girls.
Therefore the cost evidence supports:
Ferrous sulfate → best established value as first-line oral therapy.
Alternative oral formulations → potentially worthwhile when adherence/tolerance improves enough to justify their additional cost.
IV iron → highly effective but generally more resource-intensive and reserved for selected clinical circumstances.
13. When Oral Iron Is Not Enough
Failure of hemoglobin or ferritin to respond should trigger reassessment rather than simply switching brands repeatedly.
Possible explanations include incorrect diagnosis, inadequate dose, poor adherence, continued heavy menstrual loss, celiac disease or another malabsorptive condition, inflammatory disease, gastrointestinal bleeding, or another hematologic disorder.
The 2024 adolescent review recommends considering intravenous iron for persistent iron deficiency despite adequate oral therapy, severe or symptomatic IDA, or conditions associated with impaired gastrointestinal absorption.
The 2025 pediatric systematic review suggests IV iron produces a somewhat larger and faster hemoglobin response than oral therapy, although direct comparative evidence remains limited.
For a hemodynamically unstable adolescent with severe ongoing menstrual bleeding, this is no longer simply a nutritional-supplement question and urgent medical management is appropriate.
14. Practical Evidence Hierarchy
Based on the evidence reviewed, the ranking for an otherwise healthy post-menarche adolescent with confirmed iron-deficiency anemia is reasonably clear.
Strongest first-line evidence: ferrous sulfate or another conventional ferrous salt, using an appropriate elemental-iron dose with once-daily or individualized alternate-day administration.
Good alternative when conventional iron is poorly tolerated: ferric maltol, with unusually relevant new adolescent data and better palatability, but higher likely cost and no demonstrated overall efficacy superiority.
Effective but not demonstrably superior: iron polymaltose.
Promising: ferrous bisglycinate, liposomal iron, and sucrosomial iron.
Insufficient justification as stand-alone IDA treatment: folate, B12, vitamin combinations, botanical products, or ordinary multivitamins unless a separate deficiency or indication exists.
15. Conclusion: What Works and What Does Not
The strongest conclusion from contemporary evidence is that iron-deficiency anemia in menstruating adolescent girls is highly treatable, and inexpensive oral ferrous iron remains the reference therapy.
Ferrous sulfate has the most mature evidence base, generally produces strong hemoglobin and ferritin responses, is recommended by major contemporary guidance, and has the clearest cost advantage. Its principal limitation is gastrointestinal intolerance.
Newer products should not be dismissed. Ferric maltol is particularly interesting because the newest randomized pediatric trial included a predominantly female adolescent population and demonstrated meaningful improvement in hemoglobin with better taste and somewhat better treatment-related tolerability than ferrous sulfate. However, ferritin recovery was not superior, the trial was relatively small, and it was industry sponsored. Therefore, ferric maltol is better viewed as an important alternative rather than a replacement for conventional iron.
Iron polymaltose works, including the branded Maltofer preparation studied in adolescents, but pooled pediatric evidence suggests that ferrous sulfate restores hemoglobin and ferritin more effectively.
Iron bisglycinate, liposomal iron, and sucrosomial iron are plausible and increasingly supported alternatives, especially where gastrointestinal tolerance or adherence is problematic, but there is not yet enough direct evidence to claim that they produce better outcomes than ferrous sulfate in menstruating girls through age 18.
The most important clinical lesson is therefore not to search for a universally “best brand.” The best treatment is the lowest-cost evidence-supported preparation that the adolescent can tolerate, will take consistently, and that demonstrably raises hemoglobin and replenishes ferritin while the underlying cause of iron loss is simultaneously addressed.
When menstrual blood loss is excessive, simply giving more iron without evaluating and controlling the bleeding is incomplete treatment.
Selected References
Baker RD, et al. Prevention, Screening, Diagnosis, and Treatment of Iron Deficiency and Iron Deficiency Anemia in Infants, Children, and Adolescents. Pediatrics. 2026. Contemporary AAP clinical report.
DeLoughery TG, Jackson CS, Ko CW, Rockey DC. Management of Iron Deficiency Anemia. AGA Clinical Practice Update. 2024.
Powers JM, et al. Nutritional Strategies for Managing Iron Deficiency in Adolescents: Approaches to a Challenging but Common Problem. 2024. PMID 38556251.
Gass D, et al. Safety and Efficacy of Oral Ferric Maltol and Ferrous Sulfate for Iron Deficiency Anemia in Infants, Children and Adolescents: A Multicenter Randomized Trial. Paediatr Drugs. 2026. PMID 42458190.
Mohd Rosli R, et al. Effectiveness of iron polymaltose complex in treatment and prevention of iron deficiency anemia in children: a systematic review and meta-analysis. PeerJ. 2021. PMID 33520436.
Bahbah WA, et al. Liposomal SunActive versus conventional iron for treatment of iron-deficiency anemia in children aged 2–12 years: a prospective randomized controlled trial. Clin Exp Pediatr. 2025;68:608–615. PMID 40685246.
Weekly iron-folic acid supplementation and its impact on children and adolescents iron status, mental health and school performance: a systematic review and meta-analysis in sub-Saharan Africa. BMJ Open. 2024. PMID 38862227. The review searched MEDLINE, Scopus, Web of Science, Cochrane Library and Google Scholar.
Grover P, Abhilasha S. Efficacy of alternate day versus daily oral iron therapy in children with iron deficiency anemia: a randomized controlled trial. Int J Hematol. 2025. PMID 40820164.
Devaki PB, Chandra RK, Geisser P. Effects of oral supplementation with iron(III) hydroxide polymaltose complex on the hematological profile of adolescents with varying iron status. Maltofer®, Vifor (International) Inc. 2008. PMID 18807579. Included because it provides specific branded adolescent data unavailable in most recent trials.
Bruner AB, et al. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Feosol®, SmithKline Beecham. Lancet. 1996. PMID 8855856. Included as historical brand-specific female-adolescent evidence.
Medical disclaimer: This review is for educational purposes and does not provide an individualized treatment dose for a minor. Confirmed anemia, low ferritin, or heavy menstrual bleeding in an adolescent should be evaluated clinically so that the cause, severity, treatment dose, response, and duration of therapy can be appropriately monitored.
Comments